| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Sunitinib | N-(2-aminoethyl)-N-ethylnitrous amide | VE0010008 | View |
| Sunitinib | Sunitinib N-Oxide impurity | VL4380001 | View CAS 356068-99-0 |
Vancomycin Related Compound
Sunitinib is used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat to the stomach) in patients whose tumors were not successfully treated with imatinib (Gleevec) or who are unable to take imatinib.
References
- “Sunitinib: Uses, Interactions, Mechanism of Action | DrugBank Online.” Drugbank.com, DrugBank, 2021, go.drugbank.com/drugs/DB01268. Accessed 10 Mar. 2023.
- Jaini, Ritika, et al. “Combination of Sunitinib with Anti-Tumor Vaccination Inhibits T Cell Priming and Requires Careful Scheduling to Achieve Productive Immunotherapy.” International Journal of Cancer, vol. 134, no. 7, Oct. 2013, pp. 1695–705, https://doi.org/10.1002/ijc.28488. Accessed 10 Mar. 2023.
- Rizzo, Mimma, and Camillo Porta. “Sunitinib in the Treatment of Renal Cell Carcinoma: An Update on Recent Evidence.” Therapeutic Advances in Urology, vol. 9, no. 8, June 2017, pp. 195–207,https://doi.org/10.1177/1756287217713902. Accessed 10 Mar. 2023.
FAQ
What therapeutic category is sunitinib?
Sunitinib is a chemotherapeutic drug and receptor tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumors (GIST). Sunitinib is a tiny chemical that inhibits many receptor tyrosine kinases (RTKs).
Is sunitinib used in immunotherapy?
Sunitinib and other protein tyrosine kinase inhibitors have been shown to be successful therapeutics and have the potential to offer long-term and effective immunotherapy when used in conjunction with such techniques.
How is sunitinib used for renal cell carcinoma?
Sunitinib (SU011248) is a small molecule that inhibits several members of the split-kinase domain family of receptor tyrosine kinases (RTKs), including VEGFR types 1 and 2 (FLT1 and FLK1/KDR), platelet-derived growth factor receptors (PDGFR- and PDGFR-), the stem cell factor receptor c-KIT, and the FLT3 and RET kinases.
